48. Combined chemotherapy and radiation in locally advanced NSCLC  by Jassem, J.
them remain in CCR with a median tollow-up
19,5 months (range 1 to 96 months) and 66%
probability ot 8-year EFS.
Conclusions:
1. In ehildren with ALL the FTBI-12Gy-
eontaining regimen is well tolerated
without the lite-threatening toxie
eomplieations.
2. FTBI-12Gy-eontaining regimen demon-
strates very good antileukemie efficacy tor
HR-ALL in I CR, but only Iimited tor ALL in
liCA.
3. 3. In context ot good tolerance ot FTBI in
atotal dose ot 12 Gy and its Iimited
antileukemie efficacy in ehildren with ALL
in II CR the escalation ot FTBI total dose
trom 12 Gy to 13,2 Gy appears to be
justitied in those children. Suppońed by
grant KBN 4 P05E 108 18.
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COMBINED CHEMOTHERAPY AND
RADlATlON IN LOCALLy ADVANCED
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University ot Gdansk, Poland
In loeally advaneed inoperable NSCLC
radiotherapy has traditionally been considered
the mainstay of treatmenł. Unfortunately, in most
instances this method does not allow for
eradication ot bulky tumor in the thorax and does
not prevent uncontrolled systemie disease. In
consequence the prognosis of these patients is
dismai and has remained essentially unchanged
within the last decades. The five-year survival
rates after irradiation varies between 3 and 10%.
During the last decades several approaches have
been tested to improve this outcome. Of those,
particular attention has toeused on combining
chemotherapy and radiation. Two most trequently
used strategies have included induetion
ehemotherapy folIowed by radiation, or
eoncurrent ehemoradiation. The results of a few
phase III triais comparing radiation alone with
radiation supplemented by chemotherapy have
demonstrated modest yet signifieant survival
benefit from the combined approach. Two recent
studies suggested that coneomitant
ehemoradiation might be more effeetive than
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ehemotherapy preceding radiation. The gain
from the eoneurrent use ot both modalities
should however be weighted against inereased
toxicity. Further studies built upon recent
positive results should toeus on identifying
means of optimal interaetions between the two
modalities. This research should define the most
effeetive types and doses of antieancer agents
as well as the optimal teatures ot radiotherapy.
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ADJUVANT TREATMENT TO
SURGERY: IS IT STILL A PLACE FOR
RADIO-OR CHEMOTHERAPY?
P. van Houtte
Institut Jules Bordet, Brussels, Belgium
The two metaanalysis conducted by the
Cambridge group has cent the seene for
adjuvant treatment as well as the pattem of
failure analysis after surgery. In the pattem of
failure analysis peńormed after a complete
resection, local failure is a race event for
pathologieal stage 1 and II disease (less than 10
%). In opposite, for stage III, local tailure
remains an issue due to the wide range ot tumor
extent, from reseetable disease to unresectable
tumor. In eontrast, distant metastasis is a
common problem with figures ranging from 20 to
50%. A last issue is eertainly the problem ot
second cancer induced by a long history of
tobaeeo smoking rising the question of
chemoprevention.
To prevent distant metastasis, a systemie
treatment is the logical answer. The
metaanalysis suggested a slight nonsignificant
benefit for a sequential Cisplatine based
chemotherapy. The recent American trial of
Keller et al comparing postoperative
radiotherapy to a eombined ehemo-radiotherapy
approaeh did not showed any differenee for
stage III disease: the only important prognostic
tactor was the type ot mediastinal exploration:
sampling vs. radical disseetion. Several triais
are on going worldwide: Anita, ALPI, and lALT...
The main characteristics of those triais are to
include a cisplatine based chemotherapy
program and a large number ot patients. This
implies necessary a low efficacy; a smali
differenee is expeeted. Furthermore, the already
published triais showed a low eompliance to
chemotherapy.
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